{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:05:38Z","timestamp":1793502338438,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,16]]},"abstract":"<jats:sec>\n            <jats:title>Background and aims:<\/jats:title>\n            <jats:p>Nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis (NASH) is one of the primary causes of chronic liver disease worldwide. Obeticholic acid (OCA), a potent farnesoid X nuclear receptor activator, has shown promise for treating NASH-related fibrosis due to its anti-fibrotic effects. This study aimed to examine the efficacy of OCA for patients with NASH as well as to investigate its impact on dyslipidemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method:<\/jats:title>\n            <jats:p>A search of databases including PubMed, Embase, and Cochrane Library from January 1, 2010, to November 1, 2022, was conducted to identify systematic reviews of randomized controlled trials involving NASH patients. Inclusion criteria comprised randomized controlled trials that specifically addressed NASH as diagnosed through magnetic resonance imaging, computed tomography, or histology. The results were then categorized, with consideration given to both biochemical and histological outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Result:<\/jats:title>\n            <jats:p>Five NASH studies were ultimately selected for further analysis. In terms of biochemical indicators, patients receiving OCA treatment showed improvements in alanine transaminase (mean difference: \u221219.48, 95% confidence interval [CI]: \u221224.39 to 14.58; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05) and aspartate aminotransferase (mean difference: \u22129.22, 95% CI: \u221212.70 to 5.74; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). As for histological improvement, OCA treatment reduced fibrosis (odds ratio [OR]: 1.95, 95% CI: 1.47\u20132.59; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.001) and steatosis (OR: 1.95, 95% CI: 1.47\u20132.59; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.001). No significant differences were observed regarding adverse events (1.44, 95% CI: 0.57\u20133.62; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u2005.001). Regarding dyslipidemia, mean differences between total cholesterol and low-density lipoprotein were found to be high (0.33, 95% CI: 0.01\u20130.64, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05; 0.39, 95% CI: 0.04\u20130.73, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). In the case of pruritus, OCA achieved a high OR (3.22, 95% CI: 2.22\u20134.74) compared with placebo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>OCA also reduced several liver test markers compared to placebo, including the biochemical indicators alanine transaminase, aspartate aminotransferase, alkaline phosphatase, and \u03b3-glutamyl transpeptidase, and improved hepatocellular ballooning, fibrosis, steatosis, and lobular inflammation. Although the incidence of adverse events did not significantly differ between OCA and placebo groups among NASH patients, OCA treatment was found to elevate total cholesterol and low-density lipoprotein levels, and the reported severity of pruritus increased with higher doses of OCA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000037271","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T19:01:48Z","timestamp":1708110108000},"page":"e37271","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1097","volume":"103","author":[{"given":"Jie","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Nephrology, Zibo Central Hospital, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baozhen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Zibo Central Hospital, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shandong Drug and Food Vocational College, Weihai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1078-9283","authenticated-orcid":false,"given":"Zhiyong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zibo Central Hospital, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrgastro.2013.197","article-title":"NAFLD-the next global epidemic.","volume":"10","author":"Ray","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3389\/fphys.2020.00950","article-title":"Neurotropin inhibits lipid accumulation by maintaining mitochondrial function in hepatocytes via AMPK activation.","volume":"11","author":"Wang","year":"2020","journal-title":"Front Physiol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) \u2013 pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab Rev"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep4.1108","article-title":"Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice.","volume":"1","author":"Zhou","year":"2017","journal-title":"Hepatol Commun"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","article-title":"Current therapies and new developments in NASH.","volume":"71","author":"Dufour","year":"2022","journal-title":"Gut"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1026901","DOI":"10.3389\/fendo.2022.1026901","article-title":"TM6SF2 rs58542926 is related to hepatic steatosis, fibrosis and serum lipids both in adults and children: a meta-analysis.","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial.","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/hep.27999","article-title":"Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis.","volume":"62","author":"Singh","year":"2015","journal-title":"Hepatology"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.drudis.2012.05.012","article-title":"Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.","volume":"17","author":"Adorini","year":"2012","journal-title":"Drug Discov Today"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"104333","DOI":"10.1016\/j.phrs.2019.104333","article-title":"Semisynthetic bile acids: a new therapeutic option for metabolic syndrome.","volume":"146","author":"Lazarevi\u0107","year":"2019","journal-title":"Pharmacol Res"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J Med Chem"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis.","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis.","volume":"51","author":"Zhang","year":"2009","journal-title":"J Hepatol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"101675","DOI":"10.1016\/j.clinre.2021.101675","article-title":"Efficacy and safety of obeticholic acid in liver disease-a systematic review and meta-analysis.","volume":"45","author":"Kulkarni","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R25-20250504","first-page":"e24829","article-title":"Comparing the efficacy and safety of obeticholic acid and semaglutide in patients with non-alcoholic fatty liver disease: a systematic review.","volume":"14","author":"Ahmed","year":"2022","journal-title":"Cureus"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1032164","DOI":"10.3389\/fendo.2022.1032164","article-title":"Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis.","volume":"13","author":"Houttu","year":"2022","journal-title":"Front Endocrinol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"109953","DOI":"10.1016\/j.cbi.2022.109953","article-title":"Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: role of TLR4\/TGF-\u03b21 axis.","volume":"361","author":"Tawfiq","year":"2022","journal-title":"Chem Biol Interact"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ebiom.2017.08.016","article-title":"Safety, tolerability, and preliminary efficacy of the anti-fibrotic small molecule PRI-724, a CBP\/\u03b2-catenin inhibitor, in patients with hepatitis C virus-related cirrhosis: a single-center, open-label, dose escalation phase 1 trial.","volume":"23","author":"Kimura","year":"2017","journal-title":"EBioMedicine"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: regenerate 18-month interim analysis.","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3138\/canlivj-2021-0011","article-title":"Cost-effectiveness of obeticholic acid for the treatment of non-alcoholic steatohepatitis: an early economic evaluation.","volume":"4","author":"Tran","year":"2021","journal-title":"Can Liver J"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/apt.16335","article-title":"Systematic review with meta-analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma.","volume":"53","author":"Ramai","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"114497","DOI":"10.1016\/j.bcp.2021.114497","article-title":"Activation of FXR modulates SOCS3\/Jak2\/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.","volume":"186","author":"Attia","year":"2021","journal-title":"Biochem Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:17:19Z","timestamp":1746328639000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037271","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]}}}